Premium
Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in luman beings
Author(s) -
DahlPuustinen MarjaLiisa,
Lidén Anders,
Alm Christina,
Nordin Conny,
Bertilsson Leif
Publication year - 1989
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1989.109
Subject(s) - perphenazine , pharmacokinetics , pharmacology , hydroxylation , antipsychotic , clinical pharmacology , chemistry , cyp2d6 , drug , antipsychotic drug , medicine , metabolism , cytochrome p450 , psychiatry , biochemistry , enzyme , schizophrenia (object oriented programming)
The pharmacokinetics of a single oral dose of 6 mg perphenazine was studied in a group of six slow and six rapid hydroxylators of debrisoquin. Peak serum concentrations of perphenazine were significantly higher in slow hydroxylators than they were in rapid hydroxylators (2.4 ± 0.6 versus 0.7 ± 0.3 nmol/L, p < 0.001). The AUC(0–12) was also higher in slow hydroxylators than it was in rapid hydroxylators (18.5 ± 6.2 versus 4.5 ± 2.5 nmol · L −1 · hr, p < 0.001). The data suggest that the disposition of the antipsychotic drug perphenazine covaries with polymorphic debrisoquin hydroxylation. Clinical Pharmacology and Therapeutics (1989) 46, 78–81; doi: 10.1038/clpt.1989.109